Drugs / autologous bone marrow mesenchymal stem cells
autologous bone marrow mesenchymal stem cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03187431 | Dec 2017 → Oct 2018 | disease related to hematopoietic stem cell transplant | Assiut University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01854125 | May 2013 → Jan 2014 | — | Nanjing PLA General Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02564328 Comparator | Nov 2014 → Nov 2016 | ischemic stroke | Southern Medical University, China | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous bone marrow mesenchymal stem cells | “intracerebral transplantation of autologous bone marrow mesenchymal stem cells” NCT02564328 ↗ |
| Modality | Cell therapy | “bone marrow mesenchymal stem cells” NCT01854125 ↗ |
| Route | Other | “via hepatic artery” NCT01854125 ↗ |